Increasing demand for adeno-associated virus (AAV) vectors in therapeutic applications has highlighted the need for scalable and efficient methods to produce complete, high-quality AAV particles.

Advancing its LV Edge Producer technology, the synthetic biology company dealing with design and manufacture of therapeutics, has achieved unconcentrated titers with 1E9 transduction units per mL ...

In the published article, there was an error in the Funding statement. The original funding statement missed the parentheses for the full name of FORMAS and grant ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. CRISPR-Cas12a nucleases have expanded the toolbox for targeted genome engineering in a ...

The development of chimeric antigen receptor (CAR) T cell therapy has introduced a new and effective strategy to guide and promote the immune response against tumors in the clinic. More recently, in ...

Striking the Right Balance Becomes More Challenging If Co-Transfection Scenarios Are Planned Transfection technology awaits no rallying cry. It hastens from siege to siege, attacking cellular bastions ...

ABSTRACT: Background: Previous studies of patients with acute leukemia showed that plasma cGMP levels were markedly elevated before treatment, fell after successful therapy but increased after relapse ...

Case Study Involving the Use of the ExpiCHO™ Mammalian Transient Expression System The ability to produce transient CHO-derived proteins early during biotherapeutic development is highly desirable to ...

LAS VEGAS, Sept. 9, 2014 /PRNewswire/ -- Altogen Biosystems (www.altogen.com), a manufacturer of reagents for biological research, offers a broad range of animal in vivo transfection kits targeted to ...